BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ezetimibe/simvastatin (Vytorin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ezetimibe/simvastatin (Vytorin)\, from Cl
 inicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06437574-8039@assetmemo.bio
DTSTAMP:20261121T004114Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Ezetimibe/simvastatin (Vytorin): Phase 2 readout est. (NCT06437574)
DESCRIPTION:Ezetimibe/simvastatin (Vytorin)\, phase 2.\nStudy: Intensive Ch
 olesterol-Lowering and CD8+ T Cells in Prostate Cancer\nEstimated primary 
 completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/ezetimibe-simvastatin-vytorin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT06437574
URL:https://assetmemo.bio/drug/ezetimibe-simvastatin-vytorin#upcoming-event
 s
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
